3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other neoplasm
1
Gynecologic
1
Conditions
Uterine Cervical Neoplasms
3
Uterine Cervical Dysplasia
3
Uterine Neoplasms
1
Uterine Diseases
1
Uterine Cervical Diseases
1
Urogenital Neoplasms
1
Urogenital Diseases
1
Precancerous Conditions
1
Papillomavirus Infections
1
Pancreatic Neoplasms
1
Neoplasms by Site
1
Neoplasms
1
Genital Neoplasms, Female
1
Genital Diseases, Female
1
Genital Diseases
1
Female Urogenital Diseases and Pregnancy Complications
1
Acquired Immunodeficiency Syndrome
1
Interventions
Paclitaxel
6
pembrolizumab
3
Cisplatin
3
Carboplatin
3
Biopsy
3
adavosertib
2
Trastuzumab
2
Magnetic Resonance Spectroscopy
2
Fulvestrant
2
Doxorubicin
2
ulixertinib
1
tucatinib
1
trastuzumab deruxtecan
1
trastuzumab biosimilar HLX02
1
trametinib
1
selinexor
1
sapanisertib
1
sacituzumab govitecan
1
relugolix
1
relatlimab
1
pertuzumab
1
palbociclib
1
osimertinib
1
omipalisib
1
niraparib
1
larotrectinib
1
ipatasertib
1
erdafitinib
1
dostarlimab
1
dehydroftorafur
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Uterine Neoplasms
×
Acetic Acid
×
1 year
×
Clear all
NCT06815939
2026-01-29
OPTICS
DL Analytics
Phase NA
Recruiting
10,000 enrolled